Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artemether-lumefantrine intermittent screening and treatment versus sulfadoxine-pyrimethamine intermittent preventive therapy for malaria in pregnancy
PACTR202504475022266Phase 4Recruiting
- Sponsor
- Salam Tawakalt Olawumi
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of artemether + lumefantrine and sulfadoxine + pyrimethamine in malaria (2 arms), sponsored by Salam Tawakalt Olawumi. Primary endpoint: Prevalence of maternal parasitaemia at delivery. Started Feb 2024; status: recruiting.
02
Drugs
artemether + lumefantrinesulfadoxine + pyrimethamine
03
Conditions
malaria
Beyond the preview
Go deeper on PACTR202504475022266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202504475022266.